The Expression and Clinical Significance of USF1 in Newly Diagnosed Acute Myeloid Leukemia.

IF 0.7 4区医学 Q4 MEDICAL LABORATORY TECHNOLOGY

Clinical laboratory Pub Date : 2024-09-01 DOI:10.7754/Clin.Lab.2024.240419

Yuan Yuan, Yuan-Yuan Tan, Meng-Meng Zhang, Zhi-Bing Xie, Jia-Jia Li

{"title":"The Expression and Clinical Significance of USF1 in Newly Diagnosed Acute Myeloid Leukemia.","authors":"Yuan Yuan, Yuan-Yuan Tan, Meng-Meng Zhang, Zhi-Bing Xie, Jia-Jia Li","doi":"10.7754/Clin.Lab.2024.240419","DOIUrl":null,"url":null,"abstract":"Background: This study aimed to assess the expression level of upstream stimulator 1 (USF1) in the bone marrow of newly diagnosed acute myeloid leukemia (AML) patients and investigate its clinical and prognostic significance.Methods: Bone marrow samples from 60 newly diagnosed AML patients constituted the observation group, while 20 samples from healthy individuals formed the control group. Real-time quantitative PCR (qRT-PCR) was used to measure the USF1 expression in both groups and to analyze its correlation with clinicopathological features and prognosis in AML patients. Kaplan-Meier curves were utilized to assess the impact of USF1 on the overall survival (OS) in AML patients. The prognostic factors of AML were examined by using Cox regression analysis.Results: A univariate analysis revealed a significantly higher USF1 expression in the AML patients compared to the control group (p < 0.001), with no difference in the clinicopathological features between the low-expression group and the control group. However, there was a significant difference between the high-expression group and the control group (p < 0.01). Moreover, the OS of the high USF1 expression group was notably shorter than of the low USF1 expression group (p < 0.0001). A multivariate analysis identified high USF1 expression and age ≥ 60 years as independent risk factors for a poor AML prognosis.Conclusions: High expression of USF1 is linked to a worse prognosis and shorter survival time in AML patients. USF1 may serve as an indicator of prognosis and survival in AML patients and could be a potential target for AML treatment.","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"70 9","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical laboratory","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7754/Clin.Lab.2024.240419","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study aimed to assess the expression level of upstream stimulator 1 (USF1) in the bone marrow of newly diagnosed acute myeloid leukemia (AML) patients and investigate its clinical and prognostic significance.

Methods: Bone marrow samples from 60 newly diagnosed AML patients constituted the observation group, while 20 samples from healthy individuals formed the control group. Real-time quantitative PCR (qRT-PCR) was used to measure the USF1 expression in both groups and to analyze its correlation with clinicopathological features and prognosis in AML patients. Kaplan-Meier curves were utilized to assess the impact of USF1 on the overall survival (OS) in AML patients. The prognostic factors of AML were examined by using Cox regression analysis.

Results: A univariate analysis revealed a significantly higher USF1 expression in the AML patients compared to the control group (p < 0.001), with no difference in the clinicopathological features between the low-expression group and the control group. However, there was a significant difference between the high-expression group and the control group (p < 0.01). Moreover, the OS of the high USF1 expression group was notably shorter than of the low USF1 expression group (p < 0.0001). A multivariate analysis identified high USF1 expression and age ≥ 60 years as independent risk factors for a poor AML prognosis.

Conclusions: High expression of USF1 is linked to a worse prognosis and shorter survival time in AML patients. USF1 may serve as an indicator of prognosis and survival in AML patients and could be a potential target for AML treatment.

查看原文本刊更多论文

USF1 在新诊断急性髓性白血病中的表达和临床意义

背景：本研究旨在评估上游刺激因子1（USF1）在新诊断急性髓性白血病（AML）患者骨髓中的表达水平，并探讨其临床和预后意义：方法：60 例新确诊的急性髓性白血病患者骨髓样本组成观察组，20 例健康人骨髓样本组成对照组。采用实时定量 PCR（qRT-PCR）技术检测两组样本中 USF1 的表达，并分析其与 AML 患者临床病理特征和预后的相关性。利用Kaplan-Meier曲线评估USF1对AML患者总生存期（OS）的影响。结果显示，单变量分析显示，USF1与急性髓细胞性白血病（AML）患者的总生存率（OS）呈正相关：单变量分析显示，与对照组相比，急性髓细胞性白血病患者的USF1表达量明显较高（P < 0.001），低表达组与对照组的临床病理特征无差异。然而，高表达组与对照组之间存在显著差异（p < 0.01）。此外，USF1 高表达组的 OS 明显短于 USF1 低表达组（P < 0.0001）。多变量分析发现，USF1高表达和年龄≥60岁是急性髓细胞性白血病预后不良的独立危险因素：结论：USF1的高表达与急性髓细胞性白血病患者预后较差和生存时间较短有关。结论：USF1的高表达与急性髓细胞性白血病患者的预后和生存期缩短有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical laboratory 医学-医学实验技术

CiteScore

1.50

自引率

0.00%

发文量

494

审稿时长

3 months

期刊介绍： Clinical Laboratory is an international fully peer-reviewed journal covering all aspects of laboratory medicine and transfusion medicine. In addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies. The journal publishes original articles, review articles, posters, short reports, case studies and letters to the editor dealing with 1) the scientific background, implementation and diagnostic significance of laboratory methods employed in hospitals, blood banks and physicians'' offices and with 2) scientific, administrative and clinical aspects of transfusion medicine and 3) in addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies.